The anti-inflammatory CASPASE-12 gene does not influence SLE phenotype in African-Americans

• CASP12 genotype does not protect against SLE in African-Americans.
• CASP12 genotype has no correlation with any ACR classification criteria for SLE.
• CASP12+ patients were less likely to be positive for anti-dsDNA antibodies.
• CASP12 had no influence of serum IL1β levels in either controls or patients.

In the vast majority of human populations, the gene encoding CASPASE-12 (CASP12) has a premature termination codon that precludes the production of protein. However, approximately 20% of persons of recent African descent have a single nucleotide polymorphism (#rs497116; A->G) that turns the stop codon into one encoding Arg. The subsequent functional allele is a risk factor for sepsis as it uniquely downregulates inflammatory cytokines in African-Americans (AA). To determine if CASP12 could be protective for systemic lupus erythematosus (SLE) in AA, we genotyped AA SLE patients and controls. There was a weak association between CASP12 genotype with the absence of anti-dsDNA autoantibodies in SLE patients. No effect was seen upon serum interleukin-1 beta levels, nor was any other protective effect noted for the CASP12 genotype, whether upon association with SLE, or any of the 11 American College of Rheumatology classification criteria. CASP12 genotype thus does not influence the phenotype of SLE in AA.